H.R. 7035 – Biologics Market Transparency Act of 2022

AI-Generated Summary

Updated February 8, 2026 at 9:56 AM UTC

The Biologics Market Transparency Act of 2022 changes the Federal Food, Drug, and Cosmetic Act to make it easier for the government and the public to know which biologic products are actually being sold. It requires companies that hold approved applications for biologics to promptly report the marketing status of each product and to file a one‑time report within 180 days of the law’s start. The rule applies to holders of applications under both the FD&C Act and certain sections of the Public Health Service Act, affecting biologic manufacturers and the FDA’s product listings.

Key Provisions

Expands the definition of who must report to include holders of applications approved under specific sections of the Public Health Service Act, and allows reporting by abbreviated or biologics license application numbers.
Requires holders to promptly submit reports on whether each biologic product is available for sale, discontinued, withdrawn, or never marketed.
Mandates a one‑time report within 180 days of enactment confirming the availability of all listed biologic products or providing details on those withdrawn or never sold.
Updates references to the “Purple Book” list so it covers both the FD&C Act list and the Public Health Service Act list, ensuring consistent reporting across statutes.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

2 earlier actions

HouseCommittee Latest Action

Referred to the Subcommittee on Health.

Health Subcommittee

March 10, 2022

View full timeline

HouseIntro Referral

Introduced in House

March 9, 2022

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

Energy and Commerce Committee

March 9, 2022

HouseCommittee

Referred to the Subcommittee on Health.

Health Subcommittee

March 10, 2022

Bill Text

Latest available legislative text

Reading Mode

Raw Text PDF XML

Introduced in HouseIssued March 9, 2022

I

117th CONGRESS

2d Session

H. R. 7035

IN THE HOUSE OF REPRESENTATIVES

March 9, 2022

Ms. Manning (for herself and Mr. Hudson) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.

1.

Short title

This Act may be cited as the Biologics Market Transparency Act of 2022 .

2.

Prompt reports of marketing status by holders of approved applications for biological products

(a)

In general

Section 506I of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356i) is amended—

(1)

in subsection (a)—

(A)

by striking The holder of an application approved under subsection (c) or (j) of section 505 and inserting The holder of an application approved under subsection (c) or (j) of section 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act; and

(B)

in paragraph (3), by striking or abbreviated application number and inserting , abbreviated application number, or biologics license application number; and

(2)

in subsection (b)—

(A)

by striking The holder of an application approved under subsection (c) or (j) and inserting The holder of an application approved under subsection (c) or (j) of section 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act; and

(B)

in paragraph (2), by striking or abbreviated application number and inserting , abbreviated application number, or biologics license application number.

(b)

Additional one-Time report

Subsection (c) of section 506I of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356i) is amended to read as follows:

(c)

Additional one-Time report

Within 180 days of the date of enactment of the Biologics Market Transparency Act of 2022, all holders of applications approved under subsection (a) or (k) of section 351 of the Public Health Service Act shall review the information in the list published under section 351(k)(9)(A) and shall submit a written notice to the Secretary—

(1)

stating that all of the application holder’s biological products in the list published under section 351(k)(9)(a) that are not listed as discontinued are available for sale; or

(2)

including the information required pursuant to subsection (a) or (b), as applicable, for each of the application holder’s biological products that are in the list published under section 351(k)(9)(a) and not listed as discontinued, but have been withdrawn from sale or never have been available for sale.

.

(c)

Purple Book

Subsections (d) and (e) of section 506I of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356i) are each amended—

(1)

by striking the list published under subsection 505(j)(7)(A) and inserting the list published under section 505(j)(7)(A) of this Act or section 351(k)(9)(A) of the Public Health Service Act, as applicable,; and

(2)

by striking in accordance with subsection 505(j)(7)(C) and inserting in accordance with section 505(j)(7)(C) of this Act or section 351(k)(9)(B) of the Public Health Service Act (as applicable).